CONNECT WITH US
HealthTech

HealthTech

AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets

Endpoints News logo

Published on

Add as a preferred source on Google
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets

As­traZeneca says re­org could mean R&D cuts and tri­als shift­ed to emerg­ing mar­kets

As­traZeneca’s lead­er­ship hint­ed at where the cost cuts and job loss­es from the com­pa­ny’s new re­struc­tur­ing pro­gram might fall on a call …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sanofi may seek high­er Eu­ro­pean drug prices, not with­hold launch­es, un­der Trump deal October 30, 2026

For Lil­ly, cash-pay is key in the US and, in­creas­ing­ly, abroad October 29, 2026

Af­ter Be Bio shut­down, its CEO heads to Or­bis; Enan­ta's long­time chief Jay Lu­ly to re­tire

Se­tara gets $90M to con­tin­ue rare dis­ease pipeline spun out of Jaz­z's Ac­tio deal

Sanofi has no plans for a 'ma­jor' over­haul as Dupix­en­t's patent cliff looms



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.